Genomics unveiled Mystra, an AI‑enabled human‑genetics platform designed to accelerate target discovery and clinical validation by harmonizing large GWAS and multiomic datasets. The company positioned Mystra as a turnkey tool to translate genetic evidence into actionable targets backed by human data. At ASHG 2025, Genomics emphasized that targets supported by human genetic evidence show higher clinical success rates and framed Mystra as a scale solution for biopharma R&D. Separately, Anthropic’s life‑sciences team signaled its intent to bring large models into drug discovery workflows, underscoring an industry shift toward AI‑first target identification and validation. Both moves illustrate competition for market share in AI-driven target discovery, with implications for partner strategies, licensing discussions, and in‑house R&D workflows among pharma and biotech players.